Health technology assessment methodology in metastatic renal cell carcinoma

Cancer care is currently experiencing rapid development in novel therapeutics, with an associated rise in treatment costs. These changes not only create a critical challenge for therapeutic decision-making but also highlight the need to prioritize therapies of high clinical and economic value. Healt...

Full description

Saved in:
Bibliographic Details
Published in:Nature reviews. Urology 2020-01, Vol.17 (1), p.3-5
Main Authors: Parmar, Ambica, Chan, Kelvin K. W.
Format: Article
Language:English
Subjects:
692/698/1864/272
692/700/1538
692/700/155
Antimitotic agents
Antineoplastic agents
Cancer
Carcinoma, Renal Cell - secondary
Carcinoma, Renal Cell - therapy
Comment
Decision making
Health technology assessment
Homeopathy
Humans
Kidney cancer
Kidney Neoplasms - pathology
Kidney Neoplasms - therapy
Materia medica and therapeutics
Medicine
Medicine & Public Health
Metastasis
Methods
Technology application
Technology Assessment, Biomedical - methods
Therapeutics
Urology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c470t-40eb8212cde81f731ff2f8fc4ca651951b23ecb166da57263f8d90e5ad3686053
cites cdi_FETCH-LOGICAL-c470t-40eb8212cde81f731ff2f8fc4ca651951b23ecb166da57263f8d90e5ad3686053
container_end_page 5
container_issue 1
container_start_page 3
container_title Nature reviews. Urology
container_volume 17
creator Parmar, Ambica
Chan, Kelvin K. W.
description Cancer care is currently experiencing rapid development in novel therapeutics, with an associated rise in treatment costs. These changes not only create a critical challenge for therapeutic decision-making but also highlight the need to prioritize therapies of high clinical and economic value. Health technology assessment methodology is a novel approach that could help guide value-based decision-making.
doi_str_mv 10.1038/s41585-019-0257-4
format article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2312811802</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A610786593</galeid><sourcerecordid>A610786593</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-40eb8212cde81f731ff2f8fc4ca651951b23ecb166da57263f8d90e5ad3686053</originalsourceid><addsrcrecordid>eNp1kU9rFjEQxhdRbK1-AC-yIIiXrZn82-yxFLViwYueQ97s5H1TdpOaZA_99s26tbWiBJLJ5PcMM3ma5jWQUyBMfcgchBIdgaEjVPQdf9IcQy-GjitKnt7HQI-aFzlfESIl7-Xz5oiBHARwdtx8vUAzlUNb0B5CnOL-pjU5Y84zhtLOWA5x3NI-rFeTiynetgmDmVqLU91Msj7E2bxsnjkzZXx1d540Pz59_H5-0V1--_zl_Oyys7wnpeMEd4oCtSMqcD0D56hTznJrpIDa144ytDuQcjSip5I5NQ4EhRmZVJIIdtK83-pep_hzwVz07PPaigkYl6wpA6oAFKEVffsXehWXVFtfKU5ZP8geHqi9mVD74GJJxq5F9ZkE0ispBlap039QdY04exsDOl_zjwTv_hAcfn10jtNSfAz5MQgbaFPMOaHT18nPJt1oIHp1Wm9O6-q0Xp3WvGre3E227GYc7xW_ra0A3YBcn8Ie08Po_696C0x3sL0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2342379671</pqid></control><display><type>article</type><title>Health technology assessment methodology in metastatic renal cell carcinoma</title><source>Alma/SFX Local Collection</source><creator>Parmar, Ambica ; Chan, Kelvin K. W.</creator><creatorcontrib>Parmar, Ambica ; Chan, Kelvin K. W.</creatorcontrib><description>Cancer care is currently experiencing rapid development in novel therapeutics, with an associated rise in treatment costs. These changes not only create a critical challenge for therapeutic decision-making but also highlight the need to prioritize therapies of high clinical and economic value. Health technology assessment methodology is a novel approach that could help guide value-based decision-making.</description><identifier>ISSN: 1759-4812</identifier><identifier>EISSN: 1759-4820</identifier><identifier>DOI: 10.1038/s41585-019-0257-4</identifier><identifier>PMID: 31695143</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/698/1864/272 ; 692/700/1538 ; 692/700/155 ; Antimitotic agents ; Antineoplastic agents ; Cancer ; Carcinoma, Renal Cell - secondary ; Carcinoma, Renal Cell - therapy ; Comment ; Decision making ; Health technology assessment ; Homeopathy ; Humans ; Kidney cancer ; Kidney Neoplasms - pathology ; Kidney Neoplasms - therapy ; Materia medica and therapeutics ; Medicine ; Medicine &amp; Public Health ; Metastasis ; Methods ; Technology application ; Technology Assessment, Biomedical - methods ; Therapeutics ; Urology</subject><ispartof>Nature reviews. Urology, 2020-01, Vol.17 (1), p.3-5</ispartof><rights>Springer Nature Limited 2019</rights><rights>COPYRIGHT 2020 Nature Publishing Group</rights><rights>2019© Springer Nature Limited 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-40eb8212cde81f731ff2f8fc4ca651951b23ecb166da57263f8d90e5ad3686053</citedby><cites>FETCH-LOGICAL-c470t-40eb8212cde81f731ff2f8fc4ca651951b23ecb166da57263f8d90e5ad3686053</cites><orcidid>0000-0002-0597-3843</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31695143$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Parmar, Ambica</creatorcontrib><creatorcontrib>Chan, Kelvin K. W.</creatorcontrib><title>Health technology assessment methodology in metastatic renal cell carcinoma</title><title>Nature reviews. Urology</title><addtitle>Nat Rev Urol</addtitle><addtitle>Nat Rev Urol</addtitle><description>Cancer care is currently experiencing rapid development in novel therapeutics, with an associated rise in treatment costs. These changes not only create a critical challenge for therapeutic decision-making but also highlight the need to prioritize therapies of high clinical and economic value. Health technology assessment methodology is a novel approach that could help guide value-based decision-making.</description><subject>692/698/1864/272</subject><subject>692/700/1538</subject><subject>692/700/155</subject><subject>Antimitotic agents</subject><subject>Antineoplastic agents</subject><subject>Cancer</subject><subject>Carcinoma, Renal Cell - secondary</subject><subject>Carcinoma, Renal Cell - therapy</subject><subject>Comment</subject><subject>Decision making</subject><subject>Health technology assessment</subject><subject>Homeopathy</subject><subject>Humans</subject><subject>Kidney cancer</subject><subject>Kidney Neoplasms - pathology</subject><subject>Kidney Neoplasms - therapy</subject><subject>Materia medica and therapeutics</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Metastasis</subject><subject>Methods</subject><subject>Technology application</subject><subject>Technology Assessment, Biomedical - methods</subject><subject>Therapeutics</subject><subject>Urology</subject><issn>1759-4812</issn><issn>1759-4820</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp1kU9rFjEQxhdRbK1-AC-yIIiXrZn82-yxFLViwYueQ97s5H1TdpOaZA_99s26tbWiBJLJ5PcMM3ma5jWQUyBMfcgchBIdgaEjVPQdf9IcQy-GjitKnt7HQI-aFzlfESIl7-Xz5oiBHARwdtx8vUAzlUNb0B5CnOL-pjU5Y84zhtLOWA5x3NI-rFeTiynetgmDmVqLU91Msj7E2bxsnjkzZXx1d540Pz59_H5-0V1--_zl_Oyys7wnpeMEd4oCtSMqcD0D56hTznJrpIDa144ytDuQcjSip5I5NQ4EhRmZVJIIdtK83-pep_hzwVz07PPaigkYl6wpA6oAFKEVffsXehWXVFtfKU5ZP8geHqi9mVD74GJJxq5F9ZkE0ispBlap039QdY04exsDOl_zjwTv_hAcfn10jtNSfAz5MQgbaFPMOaHT18nPJt1oIHp1Wm9O6-q0Xp3WvGre3E227GYc7xW_ra0A3YBcn8Ie08Po_696C0x3sL0</recordid><startdate>20200101</startdate><enddate>20200101</enddate><creator>Parmar, Ambica</creator><creator>Chan, Kelvin K. W.</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0597-3843</orcidid></search><sort><creationdate>20200101</creationdate><title>Health technology assessment methodology in metastatic renal cell carcinoma</title><author>Parmar, Ambica ; Chan, Kelvin K. W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-40eb8212cde81f731ff2f8fc4ca651951b23ecb166da57263f8d90e5ad3686053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>692/698/1864/272</topic><topic>692/700/1538</topic><topic>692/700/155</topic><topic>Antimitotic agents</topic><topic>Antineoplastic agents</topic><topic>Cancer</topic><topic>Carcinoma, Renal Cell - secondary</topic><topic>Carcinoma, Renal Cell - therapy</topic><topic>Comment</topic><topic>Decision making</topic><topic>Health technology assessment</topic><topic>Homeopathy</topic><topic>Humans</topic><topic>Kidney cancer</topic><topic>Kidney Neoplasms - pathology</topic><topic>Kidney Neoplasms - therapy</topic><topic>Materia medica and therapeutics</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Metastasis</topic><topic>Methods</topic><topic>Technology application</topic><topic>Technology Assessment, Biomedical - methods</topic><topic>Therapeutics</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Parmar, Ambica</creatorcontrib><creatorcontrib>Chan, Kelvin K. W.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Nature reviews. Urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Parmar, Ambica</au><au>Chan, Kelvin K. W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Health technology assessment methodology in metastatic renal cell carcinoma</atitle><jtitle>Nature reviews. Urology</jtitle><stitle>Nat Rev Urol</stitle><addtitle>Nat Rev Urol</addtitle><date>2020-01-01</date><risdate>2020</risdate><volume>17</volume><issue>1</issue><spage>3</spage><epage>5</epage><pages>3-5</pages><issn>1759-4812</issn><eissn>1759-4820</eissn><abstract>Cancer care is currently experiencing rapid development in novel therapeutics, with an associated rise in treatment costs. These changes not only create a critical challenge for therapeutic decision-making but also highlight the need to prioritize therapies of high clinical and economic value. Health technology assessment methodology is a novel approach that could help guide value-based decision-making.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>31695143</pmid><doi>10.1038/s41585-019-0257-4</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0002-0597-3843</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1759-4812
ispartof Nature reviews. Urology, 2020-01, Vol.17 (1), p.3-5
issn 1759-4812
1759-4820
language eng
recordid cdi_proquest_miscellaneous_2312811802
source Alma/SFX Local Collection
subjects 692/698/1864/272
692/700/1538
692/700/155
Antimitotic agents
Antineoplastic agents
Cancer
Carcinoma, Renal Cell - secondary
Carcinoma, Renal Cell - therapy
Comment
Decision making
Health technology assessment
Homeopathy
Humans
Kidney cancer
Kidney Neoplasms - pathology
Kidney Neoplasms - therapy
Materia medica and therapeutics
Medicine
Medicine & Public Health
Metastasis
Methods
Technology application
Technology Assessment, Biomedical - methods
Therapeutics
Urology
title Health technology assessment methodology in metastatic renal cell carcinoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T17%3A30%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Health%20technology%20assessment%20methodology%20in%20metastatic%20renal%20cell%20carcinoma&rft.jtitle=Nature%20reviews.%20Urology&rft.au=Parmar,%20Ambica&rft.date=2020-01-01&rft.volume=17&rft.issue=1&rft.spage=3&rft.epage=5&rft.pages=3-5&rft.issn=1759-4812&rft.eissn=1759-4820&rft_id=info:doi/10.1038/s41585-019-0257-4&rft_dat=%3Cgale_proqu%3EA610786593%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c470t-40eb8212cde81f731ff2f8fc4ca651951b23ecb166da57263f8d90e5ad3686053%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2342379671&rft_id=info:pmid/31695143&rft_galeid=A610786593&rfr_iscdi=true